ACADIA Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
Good afternoon, everyone. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have the ACADIA team here with us today. So we have Steve Davis, CEO; and Michael Yang, Chief Commercial Officer. And with that -- thanks for joining us.
Questions & Answers
So you recently completed 2 campaigns for NUPLAZID, the first being disease awareness and then a second DTC campaign. What is -- maybe you could just walk us through the feedback post these events and provide some color on the impact you've had on NUPLAZID's prescribing activity and sales.
Yes, great. I'm going to give just a really quick lead and let Michael take the question. So what Salveen is referring to is in late 2017, we launched a disease awareness, DTC campaign, to try to fill a gap that Michael will describe
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
